November 18, 2025 7:30am

Risky assets in soft, volatile and sinking sector as breath weakens more than reflex post earnings

Pre-open Signals: 3 Positive and 3 Negative Indications and a lot of non-indications

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

 

The past, present and future values of RMi’s analysis sheds light on the cell and gene therapy’s (C&GT) sector’s “current” acrobatics 

Monday’s RMi Closing Bell: Squeaker … https://www.regmedinvestors.com/articles/14199

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

 

Tuesday: The pre-open Dow futures are DOWN -0.65% or (-307 points), the S&P futures are DOWN -0.48% or (-32 points) and the Nasdaq futures are DOWN -0.59% or (-147 points)

  • Stock futures were tumbling downward, Tuesday 11/18
  • European markets drooped,
  • Asia Pacific markets tumbled

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Monday: The Dow closed DOWN -557.24 points or -1.18%, the S&P closed DOWN -61.70 points or -0.92% while the Nasdaq closed DOWN -192.514 points or +0.84%
  • Friday: The Dow closed DOWN -309.74 points or -0.65%, the S&P closed DOWN -3.38 points or -0.05% while the Nasdaq closed UP +30.234 points or +0.13%
  • Last week: The S&P 500 was up +0.1%, the Dow +0.3% and the Nasdaq was down -0.5%.
  • The previous week: The S&P 500 was down -1.7%, the Dow -1.3% and the Nasdaq -3%
  • Last month: the S&P 500 was up +2.3%, the Nasdaq’s +4.7% and the Dow’s is up +2.5%.

 

Q4 – November, 3 positive and 8 negative sessions

  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Pre-open, I take the top 10 and bottom 10 of the previous session's closes to measure the potential of the mornings  possibles ...

CRISPR Therapeutics (CRSP) closed up +$2.79 after Friday’s +$1.42 with a negative -$0.91 or -1.64% pre-open

uniQure NV (QURE) closed up +$0.45 after Friday’s -$0.46 with a negative -$1.00 or -3.30% pre-open

IQVIA Holdings (IQV) closed down -$4.47 after Friday’s-$2.95 with a positive +$0.04 or +0.01% pre-open

Arrowhead Pharma (ARWR) closed down -$1.11 after Friday’s +$0.12 with a negative -$0.15 or -0.37% pre-open

Regenxbio (RGNX) closed down -$0.37 with a positive +$0.16 or +1.44% pre-open

MiMedx (MDXG) closed down -$0.28 with a positive +$0.20 or +2.82% pre-open

 

The BOTTOM LINE: Still feeling the what … uncertainty!

The 12th trading session of November followed a Monday negative close after a mixed week.

Are we, our sector’s portfolio circling the drain; we are ready for some rebound gains!

From someone else’s blotter:

  • “Biotech investing can feel a little bit like a Vegas sportsbook sometimes. Pick the company with the right drug trial and you could be swimming in profits. Miss that pick and you could easily see your investment getting cut in half.” <Motley Fool>
  • A pair of macro tailwinds are building that could drive biotech returns heading into 2026. The sector has been outperforming the S&P 500 since August, and the trend could still be in the early innings.
  • Let's look at what's driving the biotech sector right now and why the SPDR S&P Biotech ETF (NYSEMKT: XBI) could be a great way to play the sector.
  • If there's one downside to the biotech sector, it's time. From discovery to approval, new drugs can take 10 years before they finally hit the market. Along the way, companies may spend millions of dollars pushing a treatment through the process, all in the hope of generating revenue from it at some point years down the road. It's estimated that fewer than 10% of the drugs that enter the clinical trial stage ultimately get approved for commercial use.
  • It's a big reason why biotech investing can be a "feast or famine" proposition and why it comes with a high degree of risk.

Expect earnings’ results that meet, beat or miss revenue estimates, EPS as to pricing expectations, consensus … sector earnings while LPS (loss-per-share) assumes adjustments

Welcome to my world of defining the “grey’ in our universe!

  • As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

November to understand the flow:

This week:

  • 11/17 – Monday closed negative with 19 positive, 20 negative and 1 flat

Last week:

  • 11/14 - Friday closed negative with 19 positive, 21 negative and 0 flats
  • 11/13 – Thursday closed negative with 8 positive, 32 negative and 0 flat
  • 11/12 – Wednesday closed negative with 18 positive, 22 negative and 0 flat
  • 11/11 – Tuesday closed positive with 34 positive, 4 negative and 2 flats
  • 11/10 - Monday closed positive with 26 positive, 14 negative and 0 flats

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.